glenmark
A new way for a new world

March 7, 2012

The Manager
Listing Dept,
The National Stock Exchange of India Ltd
Plot No.C/1,G Block
Bandra Kurla Complex
Bandra (E) Mumbai-400051

Dear Sir,

We are enclosing herewith a press release informing "**Glenmark Generics receives USFDA approval for Imiquimod Cream**", for your information and record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

Marshall Mendonza
Vice President & Company Secretary

Tel: 4018 9999 / 4018 9879 Fax No. 4018 9986 (Legal & Secretarial Dept.)

Encl: as above

Press Release **For Immediate Release**

Glenmark Generics receives USFDA approval for Imiquimod Cream

March 7, 2012: Glenmark Generics Inc., USA the subsidiary of Glenmark Generics Limited has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (U.S. FDA) for Imiquimod Cream 5%, their generic version of Aldara® by Medicis Pharmaceutical Corporation. and has commenced shipping immediately upon approval.

Imiquimod Cream 5% is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults and for the treatment of external genital and perianal warts/condyloma acuminate in patients 12 years old or older. According to IMS Health sales data for the 12 month period ending December 2011, Imiquimod Cream garnered annual sales of approximately USD 244 million.

Glenmark's current portfolio consists of 77 products authorized for distribution in the U.S. marketplace and 40 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

About Glenmark Generics Limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:
Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India
Tel: [+91 22] 40189919
Email : connect@glenmark-generics.com